WO2026067609 - PEGYLATED LIPID MODIFIED WITH TARGETING LIGAND, RELATED COMPOSITION AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2026/067609
Publication Date
02.04.2026
International Application No.
PCT/CN2025/124304
International Filing Date
26.09.2025
Title **
[English]
PEGYLATED LIPID MODIFIED WITH TARGETING LIGAND, RELATED COMPOSITION AND USE THEREOF
[French]
LIPIDE PEGYLÉ MODIFIÉ AVEC UN LIGAND DE CIBLAGE, COMPOSITION ASSOCIÉE ET UTILISATION ASSOCIÉE
[Chinese]
靶向配体修饰的聚乙二醇化脂质，相关的组合物及其应用
Applicants **
XIAMEN SINOPEG BIOTECH CO., LTD
Inventors
LIN, Sheng
CHEN, Dandan
WANG, Ailan
WEI, Guohua
LIN, Congming
ZHU, Qi
WENG, Wengui
LIU, Chao
Priority Data
202411350428.9
26.09.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2657 | |
| EPO | Filing, Examination, Granting | 19521 | |
| Japan | Filing, Examination, Granting | 2493 | |
| South Korea | Filing, Examination, Granting | 2861 | |
| USA | Filing, Examination, Granting | 6390 |
Total:
33,922
Contact Us
Abstract[English]
and M are divalent linking groups. The targeting PEGylated lipid of the present invention significantly improves the in vitro and in vivo targeting effects of lipid nanoparticles, and can achieve more efficient delivery of liver-targeting drugs.[French]
et M étant des groupes de liaison divalents. Le lipide pegylé de ciblage de la présente invention améliore significativement les effets de ciblage in vitro et in vivo de nanoparticules lipidiques, et peut procurer une administration plus efficace de médicaments ciblant le foie.[Chinese]
和M为二价连接基。本发明的靶向性聚乙二醇化脂质显著提升了脂质纳米粒的体外和体内的靶向效果，可实现更为高效的肝靶向药物递送。